What are the treatment attributes preferred by UK patients with transthyretin amyloid cardiomyopathy?

9 May 2026 (08:00 - 12:45)

Organised by:

Sign in to view the resources

About the speaker

Doctor Louis Baig

Pfizer UK, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail

Impact of an educational intervention on pharmacological management of HFrEF in Italy: results from the multicenter OpTIMa-HF registry

Doctor M. Di Santo (Naples, IT)

Presentation thumbnail

Renal function and therapeutic inertia: a gap between eligibility and prescription of guideline-directed medical therapy in hospitalized reduced and mildly reduced ejection fraction patients

Doctor M. Silva (Amadora, PT)

Presentation thumbnail

Natriuretic response as a marker of decongestion in hospitalized patients with heart failure

Doctor S. Singh (Hartford, US)

Presentation thumbnail

No phenotype-based differences in discharge GDMT across the LVEF spectrum in acute heart failure: data from multicenter registry

Doctor M. Balabayeva (Aktobe, KZ)

Presentation thumbnail

Early initiation of SGLT2-inhibitors and changes in physical function in elderly patients hospitalized for heart failure

Doctor Y. Nishihata (Tokyo, JP)

Access the full session

Session thumbnail

ePosters in acute heart failure - pharmacotherapy (2)

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

You may be interested in

Congress Session

Acute heart failure therapies: from clinical trials to clinical practice

Congress Session

Devices in acute heart failure

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources